Role of STAT3 in Cancer Metastasis and Translational Advances

Table 3

Selected JAK inhibitors currently being evaluated in clinical trials for autoimmunity and cancer.

Inhibitor	Targeted JAK	Phase in development
Ruxolitinib	JAK2, JAK1	FDA approved for myelofibrosis; Phase II in prostate cancer,; hematological malignances
Tofacitinib	JAK3, JAK1	FDA approved for rheumatoid arthritis
SAR302503	JAK2, JAK1	Phase I in solid tumors; Phase III in myelofibrosis
CYT387	JAK2, JAK1	Phase II in myelofibrosis
Pacritinib	JAK2	Phase II in hematologic malignancies
AZD1480	JAK2, JAK1	Phase I in solid tumors
INCB028050	JAK2, JAK1	Phase II in rheumatoid arthritis